May 9th 2024
Leading dermatologists explore key benchmarks, emerging trends, personalized medicine approaches, and more in atopic dermatitis.
Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis
View More
Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?
View More
"REEL" Time Patient Counseling™: Integrating Biosimilars into the Clinical Conversation
View More
PER Skin Summit: Optimizing Diagnosis and Individualizing Management of Hidradenitis Suppurativa
View More
Community Practice Connections™: 19th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®
View More
Expert Illustrations & Commentaries™: A Deeper Look at the Pathogenesis of Hidradenitis Suppurativa (HS)
View More
Cancer Summaries and Commentaries™: Clinical Updates in Melanoma from Philadelphia
View More
Expert Illustrations & Commentaries™: Picturing the Potential Role of OX40 and OX40L Inhibitors in Atopic Dermatitis
View More
Hidradenitis Suppurativa (HS): Deepening Foundations of Knowledge in Disease Pathogenesis, Disease Severity Assessment, and Treatment Decision-Making
View More
Molecular study highlights drug differences in atopic dermatitis
April 20th 2020A recent meta-analysis confirms cyclosporine as the most effective atopic dermatitis (AD) treatment at the molecular level, although dupilumab achieves broad cutaneous changes beyond those expected with specific Th2 inhibition.
LEO Pharma enters agreement to develop novel drug for atopic dermatitis, asthma
April 15th 2020LEO Pharma has entered into a license agreement with Oneness Biotech and Microbio Shanghai for the development and commercialization of the investigational drug FB825 for the treatment of atopic dermatitis and asthma.
Atopic dermatitis patients need better disease control
March 17th 2020Adult patients with moderate-to-severe atopic dermatitis who were treated with systemic agents, including cyclosporine, azathioprine, mycophenolate mofetil, methotrexate or cyclophosphamide, reported a high level of disease-related burden despite those treatments, says a recent study.
Atopic dermatitis pipeline full of potential
March 9th 2020Atopic dermatitis therapy is currently undergoing a revolution that promises to treat patients of all ages who are suffering from every aspect of the disease-from rashes, itch and sleep disturbances, to secondary effects, like anxiety and depression.
Atopic dermatitis treatment hurdles
February 25th 2020It’s an exciting time for atopic dermatitis patients as many new treatment options are on the market and in the pipeline. But treatment doesn’t yet offer a cure and many patients continue to suffer with symptoms, including itch, psychosocial and quality-of-life issues, according to a recent paper.
Molecular mechanisms that disrupt the epidermal barrier
February 25th 2020Abnormalities in epidermal barrier integrity, affecting factors such as epidermal calcium gradients, filaggrin, cornified envelopes, desquamation of corneodesmosomes and skin lipids, may also influence epidermal barrier dysfunction, according to a recent review.
Eczematous eruptions in psoriasis patients using IL-17 inhibitors
February 21st 2020A recent chart review found that eczematous eruptions occurred in 5.8% of patients using interleukin (IL)-17 inhibitors for psoriasis. Its authors believe that additional research could help identify which patients may be most at risk.
Oral JAK inhibitor appears safe, effective for atopic dermatitis
February 17th 2020Eli Lilly and Incyte announces positive results of two phase 3 clinical trials investigating the use of JAK inhibitor baricitinib as both a monotherapy and combination therapy for moderate-to-severe atopic dermatitis.
FDA grants priority review for dupilumab in pediatric AD
January 31st 2020The FDA announced it has accepted a priority review of dupilumab for the treatment of moderate-to-severe AD in pediatric patients 6 to 11 years of age. The drug is already approved for treatment of AD in adolescents and adults.
Skin microbiome as clinical biomarker for atopic dermatitis
January 21st 2020With advancements in deep next-generation sequencing (NGS) and bioinformatics analysis, the authors of a recent study suggest the skin microbiome may hold promise as a clinical biomarker in atopic dermatitis (AD) management.
Moisturizers offer easy, low-cost option for kids with atopic dermatitis
January 16th 2020Anneke Andriessen, Ph.D. discusses research that suggests controlling symptoms with moisturizers can be an important - and inexpensive - prevention and treatment tactic for pediatric patients with atopic dermatitis.
Tralokinumab meets endpoints for all phase 3 studies
December 16th 2019LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
Tape strips may replace biopsies in pediatric atopic dermatitis
December 13th 2019Biopsies are the gold standard approach for obtaining skin samples to test for biomarkers in atopic dermatitis, but tape strips may offer a far less invasive alternative for young children with the disease, research suggests.
High risk of conjunctivitis in atopic dermatitis patients
December 12th 2019Dermatologists should look for signs of conjunctivitis in their atopic dermatitis patients and learn how to manage the condition because this patients population may have an increased risk of experiencing conjunctivitis, particularly allergic conjunctivitis, according to a recent study.